Brief Report: Combination Capmatinib and Trametinib in Metastatic MET-Driven NSCLC

Introduction

MET tyrosine kinase inhibitor (TKI) therapy has improved outcomes in patients with NSCLC harboring MET alterations. Nevertheless, primary and acquired resistance ultimately limit the durability of response. This study evaluated the safety and efficacy of the MET inhibitor capmatinib with the MEK inhibitor trametinib in patients with metastatic MET-driven NSCLC who had progressed on prior treatment with at least one MET inhibitor.